Chlamydia trachomatis is the most common bacterial sexually transmitted disease in the
world and specifically in the United States, with the highest incidence in age-groups 14–19 …

To search for optimal immunization conditions for inducing protective immunity against
upper genital tract pathologies caused by chlamydial intravaginal infection, we compared …

Chlamydia trachomatis infections can occur early in life and may result in long-term
sequelae. To assess the feasibility of implementing a vaccine in newborns, groups of 2-day …

In an attempt to confer long-term protective immunity, BALB/c female mice were immunized
intranasally with 10 (4) inclusion-forming units (IFU) of the Chlamydia trachomatis mouse …

Chlamydia pneumoniae causes a range of respiratory infections including bronchitis,
pharyngitis and pneumonia. Infection has also been implicated in exacerbation/initiation of …

Guinea pigs have been used as a second animal model to validate putative anti-chlamydial
vaccine candidates tested in mice. However, the lack of guinea pig-specific reagents has …

To determine the role of maternal immunity in protecting newborn mice against a Chlamydia
trachomatis infection, female BALB/c mice were immunized intranasally (in) with 104 …

Background The chlamydial proteins CT443 (OmcB) and CT521 (rl16) have previously been
identified as human B and/or T cell targets during a chlamydial infection in humans. Here we …

There is currently no licensed vaccine against Chlamydia trachomatis, the leading cause of
sexually transmitted bacterial disease worldwide. Conventional vaccination attempts using …

Female BALB/c mice were immunized intranasally with the mouse pneumonitis biovar of
Chlamydia trachomatis and subsequently challenged in the ovarian bursa (C. trachomatis …